Source: International Congress 2017 – Late-breaking findings in pulmonary diseases
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
E. Murphy (Glasnevin, Ireland). Late Breaking Abstract - Enhancing the antimicrobial efficacy of mesenchymal stem cells (MSCs) to combat sepsis-induced acute lung injury (ALI) using a novel combination of immune-stimulants. 2813

Member's Comments

No comment yet.

Related content which might interest you: Mesenchymal stromal (stem) cell therapy modulates miR-193b-5p expression to attenuate sepsis-induced acute lung injury Source: Eur Respir J, 59 (1) 2004216; 10.1183/13993003.04216-2020 Year: 2022 Effects of autologous mesenchymal stromal cell treatment for severe emphysema on lung tissue: A clinical trial Source: International Congress 2015 – The multiple facets of stem and progenitor cells in lung health and disease Year: 2015 Mesenchymal stromal cells (MSC) anti-microbial effect in acute respiratory distress syndrome (ARDS) is mediated in part by enhanced alveolar macrophage phagocytosis through cell contact-dependent mitochondrial transfer leading to improved macrophage bioenergetics Source: International Congress 2016 – Novel insights into alveolar and bronchial epithelial cell injury and repair Year: 2016 Therapeutic potential of mesenchymal stem cells to attenuate immune cell tolerance in a late stage model of sepsis Source: Virtual Congress 2020 – Physiological and cellular mechanisms affecting pulmonary pathologies Year: 2020 Intratracheal application of healthy lung derived Mesenchymal Stem Cells (DON-MSC) in the form of biospheres (BS) as potential therapeutic agents for chronic lung disease Source: Virtual Congress 2020 – Translational therapeutic advances Year: 2020 The new-defined mesenchymal stromal/stem cell marker has a protective role in the development of acute lung injury. Source: International Congress 2019 – Involvement of the environment and inflammation in pulmonary remodelling Year: 2019 Secreted mediators from induced pluripotent stem cells (iPSc) attenuate fibrosis in bleomycin injured rat lung Source: Annual Congress 2012 - Stem cells and progenitors in injury and repair Year: 2012 Immunotherapeutic strategy with mesenchymal stem cells modulating inflammation in an experimental model of COPD. Source: Virtual Congress 2020 – New insight into the immunology of asthma and COPD Year: 2020 Successful transplantation of rat mesenchymal stem cells, for the therapy of bleomycin induced lung injury Source: Annual Congress 2010 - Determinants of acute lung injury and fibrosis Year: 2010 Effect of low level laser (LLL) and mesenchymal stem cells (htMSCs) therapies on cigarette-induced lung inflammation in mice Source: Annual Congress 2013 –Tobacco use in different countries: crisis to disease Year: 2013 Mesenchymal stem cell based angiopoietin-1 gene therapy for acute lung injury induced by lipopolysacharride in mice Source: Annual Congress 2008 - Border patrol: the alveolar barrier in lung injury Year: 2008 Mesenchymal stem cell-conditioned medium induces neutrophils apoptosis via inhibition of NF-kB pathway and increases endogenous pulmonary stem cells in endotoxin-induced acute lung injury Source: International Congress 2015 – The multiple facets of stem and progenitor cells in lung health and disease Year: 2015 Effects of hypercapnic acidosis on the primary cells relevant to ARDS pathophysiology and the therapeutic potential of mesenchymal stem cells Source: International Congress 2017 – Anti-inflammatory and pro-repair mediators in acute lung injury Year: 2017 Which is the best source of mesenchymal cells to treat acute lung injury? Source: Annual Congress 2011 - Mechanisms of acute lung injury and mesenchymal cell treatment Year: 2011 Synergistic effect of human tubal mesenchymal stem cell (htMSCs) and low level laser (LLL) therapy significantly reduces experimental COPD in mice Source: International Congress 2014 – Animal models in respiratory drug development Year: 2014 Late Breaking Abstract - Mesenchymal stromal cells as a salvage treatment for persistent ARDS Source: Virtual Congress 2020 – New insights into mechanical ventilation in the intensive care unit Year: 2020 Late Breaking Abstract - Mesenchymal stromal cell exosomes prevent and revert experimental pulmonary fibrosis through systemic modulation of monocyte phenotypes Source: International Congress 2018 – ILDs: From bench to bedside Year: 2018 Pre-treatment with mesenchymal stem cells reduces ventilator-induced lung injury}, Source: Eur Respir J 2012; 40: 939-948 Year: 2012